The linearly decreasing convergence factor a. حسب Junhao Wei (6816803)

Baseline patient characteristics. حسب Oscar F. C. van den Bosch (22184246)

الموضوعات:

Association of each health behavior and the reported decrease in psychological well-being during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors. Results are predicted means and 95% confidence intervals from linear model analysis adjusted for age, gender, worked in patient care, had school aged children, near high-risk relatives and in high-risk group.... حسب Elie Mulhem (22537863)

الموضوعات:

Effect of each health behavior on the reported decrease in physical health during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors. Results are predicted means and 95% confidence intervals from linear model analysis adjusted for age, gender, worked in patient care, had school aged children, near high-risk relatives and in high-risk group.... حسب Elie Mulhem (22537863)

الموضوعات:

Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" حسب Kira Shaw (18796168)

"…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". The following acronyms included in the CSV file are defined as follows: Hbt is total hemoglobin, Art is artery region, DV is draining vein region, WV is whisker vein region, SEM is standard error mean, TS is time series, max peak is maximum peak, min peak is minima, AUC is area under the curve, WT is wild-type, AD is Alzheimer's disease, ATH is atherosclerosis and MIX is mixed AD/atherosclerosis. …"

Effects of s-ketamine and midazolam on respiratory parameters. حسب Oscar F. C. van den Bosch (22184246)

الموضوعات:

Flow chart of the study participants. حسب Oscar F. C. van den Bosch (22184246)

الموضوعات:

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. حسب Gui Araujo (22170819)

"…(C) Mutualism also promotes an increase in network connectance when introduced into assembled communities, while stopping mutualistic interactions from entering an assembled system slowly decreases it. (D) As a result, the introduction of mutualistic interactions promotes a growth in complexity in communities where it was once established as low, while stopping the introduction of further mutualistic interactions causes a slight decrease in complexity. …"

Association between the sum of health behaviors and decrease in physical health from before to during the pandemic. Results are from linear model analysis adjusted for age, gender and additional covariates.... حسب Elie Mulhem (22537863)

الموضوعات:

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات: